M.E.H.M Hoef

Intensive and/or dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or equivalent in acute leukemia followed by an non-myeloablative reduced intensity conditioning allogeneic transplants in patients with donor compared to patients without donor (AML, ALL, CML, HD, NHL, neuroblastoma)

Protocol for CML until molecular complete remission has been obtained followed by a non-myeloablative reduced intensity conditioning allogeneic transplant within 12 months from diagnosis.

Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for multiple myeloma.

Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for neuroblastoma.

Dose dense induction chemotherapy, two semi-high-dose conditioning autologous peripheral blood progenitor cell transplant and a non-myeloablative reduced intensity conditioning allogeneic stem cell transplants in patients with and without donor for lymph node 4+ and to the bone marrow metastasized breast cancer

Multicenter phase I-II study of intensified induction and consolidation chemotherapy with autologous PBPC infusion followed by non-myeloablative HLA-identical sibling transplant for early metastatic breast cancer.

Intensive and/or dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or equivalent in acute leukemia followed by an non-myeloablative reduced intensity conditioning allogeneic transplants in patients with donor compared to patients without donor (AML, ALL, CML, HD, NHL, MM).